{"id":"W4379333780","doi":"10.1200/jco.2023.41.16_suppl.tps7590","title":"MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"BeiGene","keywords":"Medicine; Obinutuzumab; Lenalidomide; Rituximab; Internal medicine; Ibrutinib; Oncology; Idelalisib; Follicular lymphoma; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Gastroenterology; Lymphoma; Leukemia; Multiple myeloma; Tyrosine kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.006868003,0.0003680895,0.004364887,0.000791115,0.00007053538,0.0000193212,0.0004993326,0.0007660447,0.0003175795],"category_scores_gemma":[0.01446389,0.0002159602,0.0006471957,0.001100991,0.0007999631,0.0002543398,0.0002297065,0.001256658,0.00006595389],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.006906559,"about_ca_system_score_gemma":0.05541712,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002331712,"about_ca_topic_score_gemma":0.0001412601,"domain_scores_codex":[0.9910991,0.001132576,0.004633226,0.0005114828,0.001804941,0.0008186357],"domain_scores_gemma":[0.9886459,0.00628844,0.002837899,0.0005954256,0.0009833033,0.0006490965],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9301945,0.01389041,0.00432978,0.0002972372,0.0009279969,0.01764075,0.0002573481,0.00005627771,0.00007061152,0.00001675449,0.00532303,0.02699529],"study_design_scores_gemma":[0.864,0.0898437,0.02284736,0.0007942781,0.0005427056,0.0005364217,0.0002554998,0.001862106,0.0001103158,0.00002265958,0.01895352,0.0002314278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952981,0.0001548556,0.00007066557,0.001589234,0.001289807,0.001198744,0.00002526633,0.00003184521,0.0003414083],"genre_scores_gemma":[0.9939958,0.001265993,0.001657601,0.0004826616,0.001050879,0.00001680461,0.00003116522,0.00006992921,0.001429158],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07595329,"threshold_uncertainty_score":0.9969057,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1181807333488685,"score_gpt":0.4680301710243539,"score_spread":0.3498494376754854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}